Enlivex Secures $400M Private Placement at Premium

Enlivex Ltd. announced a private placement agreement with a single institutional investor to raise $400,000,000. The shares are priced at a premium of 17.4% to 40.8% depending on the funding method, with the investor initially opting to use RAIN tokens. The company plans to use the net proceeds to advance its treasury strategy built around the Rain protocol and to further develop Allocetra™, its immunotherapy for age-related osteoarthritis. Additionally, Enlivex has the option to require the investor to purchase up to an extra $400,000,000 in shares over the next 36 months, pending shareholder approval.